Ken Hsu is scientific founder of a new startup biotech company that launched this week with $56M in seed financing. Hyku Biosciences aims to develop covalent oncology drugs based on advancing Hsu’s sulfur–triazole exchange (SuTEx) chemistry.
https://www.hykubiosciences.com/news-media/press-release-9-19-23
A new study from the Hsu Lab in collaboration with colleagues at Princeton report the discovery of small molecules capable of controlling cellular levels of membraneless subcellular compartments known as processing-bodies (PBs) and stress granules (SGs). PBs and SGs are cytoplasmic ribonucleoprotein granules that are part of a larger family of stru...
The Department of Chemistry is pleased to announce that Dr. Ku-Lung (Ken) Hsu will join the University of Texas at Austin in 2023 as a CPRIT Scholar. Dr. Hsu will bring his innovative program in chemical biology, focusing on protein biology and metabolism to develop new pharmacological approaches for cancer and immunology.